These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32801864)

  • 1. Aberrant Expression of Citrate Synthase is Linked to Disease Progression and Clinical Outcome in Prostate Cancer.
    Cai Z; Deng Y; Ye J; Zhuo Y; Liu Z; Liang Y; Zhang H; Zhu X; Luo Y; Feng Y; Liu R; Chen G; Wu Y; Han Z; Liang Y; Jiang F; Zhong W
    Cancer Manag Res; 2020; 12():6149-6163. PubMed ID: 32801864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
    Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
    Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
    Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
    Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
    Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
    Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression of SLC 39A14 is associated with tumor aggressiveness and biochemical recurrence of human prostate cancer.
    Xu XM; Wang CG; Zhu YD; Chen WH; Shao SL; Jiang FN; Liao QD
    Onco Targets Ther; 2016; 9():4197-205. PubMed ID: 27471394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycyl-tRNA Synthetase (GARS) Expression Is Associated with Prostate Cancer Progression and Its Inhibition Decreases Migration, and Invasion In Vitro.
    Khosh Kish E; Gamallat Y; Choudhry M; Ghosh S; Seyedi S; Bismar TA
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eya2 Is Overexpressed in Human Prostate Cancer and Regulates Docetaxel Sensitivity and Mitochondrial Membrane Potential through AKT/Bcl-2 Signaling.
    Liu Z; Zhao L; Song Y
    Biomed Res Int; 2019; 2019():3808432. PubMed ID: 31317026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
    Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
    BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis.
    Xu N; Wu YP; Yin HB; Chen SH; Li XD; Xue XY; Gou X
    J Cancer Res Clin Oncol; 2020 Aug; 146(8):1953-1969. PubMed ID: 32447485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
    Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
    Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.
    Ling XH; Han ZD; Xia D; He HC; Jiang FN; Lin ZY; Fu X; Deng YH; Dai QS; Cai C; Chen JH; Liang YX; Zhong WD; Wu CL
    Mol Biol Rep; 2014 May; 41(5):2779-88. PubMed ID: 24452717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of SOCSs in human prostate cancer and their association in prognosis.
    Zhu JG; Dai QS; Han ZD; He HC; Mo RJ; Chen G; Chen YF; Wu YD; Yang SB; Jiang FN; Chen WH; Sun ZL; Zhong WD
    Mol Cell Biochem; 2013 Sep; 381(1-2):51-9. PubMed ID: 23666742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant KIF20A Expression Is Associated with Adverse Clinical Outcome and Promotes Tumor Progression in Prostate Cancer.
    Zhang Z; Chai C; Shen T; Li X; Ji J; Li C; Shang Z; Niu Y
    Dis Markers; 2019; 2019():4782730. PubMed ID: 31565099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. m
    Lang C; Yin C; Lin K; Li Y; Yang Q; Wu Z; Du H; Ren D; Dai Y; Peng X
    Clin Transl Med; 2021 Jun; 11(6):e426. PubMed ID: 34185427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer.
    Fu X; Chen G; Cai ZD; Wang C; Liu ZZ; Lin ZY; Wu YD; Liang YX; Han ZD; Liu JC; Zhong WD
    Onco Targets Ther; 2016; 9():2211-20. PubMed ID: 27143916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
    Zeng X; Hu Z; Wang Z; Tao J; Lu T; Yang C; Lee B; Ye Z
    Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCGEM1 promotes proliferation, migration and invasion in prostate cancer by sponging miR-506 to upregulate TRIAP1.
    Liu H; He X; Li T; Qu Y; Xu L; Hou Y; Fu Y; Wang H
    BMC Urol; 2022 Feb; 22(1):14. PubMed ID: 35109849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of long noncoding RNA LOC440040 promotes tumor progression and predicts poor prognosis in patients with prostate cancer.
    Zhang C; Liu C; Wu J; Zheng Y; Xu H; Cheng G; Hua L
    Onco Targets Ther; 2017; 10():4945-4954. PubMed ID: 29066914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.